Biotin

Biotin

SCHEMBL565572

NCCCCCN.NCCCCCNC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12.O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 5/20 0.72
▸ MEN1 O00255 1/20 0.69
▸ ABL1 P00519 1/20 0.69
▸ LMNA P02545 1/20 0.69
▸ PKM P14618 1/20 0.69
▸ IDE P14735 1/20 0.69
▸ MAPK1 P28482 1/20 0.69
▸ KMT2A Q03164 1/20 0.69
▸ RIN1 Q13671 1/20 0.69
▸ L3MBTL1 Q9Y468 1/20 0.69
▸ FOLH1 Q04609 2/20 0.59
▸ CA12 O43570 3/20 0.58
▸ CA1 P00915 3/20 0.58
▸ CA2 P00918 3/20 0.58
▸ CA9 Q16790 3/20 0.58
▸ PLCD1 P51178 1/20 0.56
▸ CAPN1 P07384 2/20 0.55
▸ ITGB1 P05556 1/20 0.54
▸ ITGA4 P13612 1/20 0.54
▸ PRSS1 P07477 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biotin SCHEMBL27757189 1.00 TDP1 (0.72) TDP1MEN1ABL1LMNAPKM
SCHEMBL20375017 0.96 TDP1 (0.74) TDP1MEN1ABL1LMNAPKM
SCHEMBL288457 0.96 TDP1 (0.74) TDP1MEN1ABL1LMNAPKM
SCHEMBL316398 0.96 TDP1 (0.74) TDP1MEN1ABL1LMNAPKM
SCHEMBL10308271 0.96 TDP1 (0.74) TDP1MEN1ABL1LMNAPKM
SCHEMBL10140226 0.96 TDP1 (0.74) TDP1MEN1ABL1LMNAPKM
SCHEMBL13049579 0.96 TDP1 (0.74) TDP1MEN1ABL1LMNAPKM
SCHEMBL9733492 0.96 TDP1 (0.74) TDP1MEN1ABL1LMNAPKM
SCHEMBL20483620 0.96 TDP1 (0.74) TDP1MEN1ABL1LMNAPKM
SCHEMBL13065003 0.96 TDP1 (0.74) TDP1MEN1ABL1LMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035105-A1 Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments SDG, INC. 2012-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035105-A1 Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments IAPP, IDE, INSR TDP1 2829/4885MEN1 1048/4885ABL1 2517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback